Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OneMedNet Corp filings document the public-company reporting record for a healthcare data business with common stock and redeemable warrants. Recent 8-K reports cover Nasdaq continued-listing matters, including minimum bid price and market-value compliance notices, along with other material events affecting the company’s public listing status.
Proxy materials describe annual meeting procedures, stockholder voting matters, board composition, and governance disclosures. The filing record also identifies the company’s capital securities, including common stock and redeemable warrants exercisable for common shares, and records director-related governance updates through current reports.
OneMedNet Corporation is registering up to 11,680,535 shares of Common Stock for resale by existing stockholders under a Form S-1 registration statement. The shares include up to 8,500,000 issuable under a $25 million Standby Equity Purchase Agreement with Yorkville plus stock previously issued to two insiders for cash investments and compensation.
The company will not receive proceeds from stockholder resales, though it may raise cash directly from Yorkville through future share advances priced at 97% of market, subject to ownership and 19.99% exchange caps. OneMedNet provides healthcare software for managing and curating medical imaging Real World Data, but reports recurring losses, a substantial accumulated deficit and an auditor going concern warning.
As of June 30, 2026, 56,952,652 shares were outstanding, and ONMD traded at $0.711 on the Nasdaq Capital Market, where it faces a bid-price deficiency notice. The prospectus highlights significant business, dilution, regulatory, cybersecurity, bitcoin-holding and volatility risks for investors.
OneMedNet Corporation has filed an S-1 registering up to 11,680,535 shares of common stock for resale by existing holders. This includes up to 8,500,000 shares issuable under a $25 million Standby Equity Purchase Agreement with Yorkville and additional shares held by directors Dr. Thomas Kosasa and Dr. Jeffrey Yu, including stock issued in lieu of cash compensation.
The company will not receive proceeds from resale of these registered shares, though it may raise capital through future share advances to Yorkville. As of June 30, 2026, OneMedNet had 56,952,652 shares outstanding and its stock closed at $0.711 on Nasdaq under the symbol ONMD.
The filing highlights significant risks: a history of losses with net losses of $2.8 million in 2025 and $10.1 million in 2024, an accumulated deficit of about $104.4 million, a going-concern warning from auditors, potential Nasdaq delisting for not meeting the $1.00 minimum bid price, substantial potential dilution from SEPA and insider-held shares, and exposure to bitcoin price volatility.
OneMedNet Corporation entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. that allows the company, at its option, to sell up to $25 million of common stock over time. Sales can begin only after a resale registration statement for these shares becomes effective.
The agreement runs for 36 months. Each advance is limited to the greater of 500,000 shares and 100% of the stock’s five-day average trading volume, and is priced at 97% of the Market Price as defined in the agreement. Yorkville cannot exceed 4.99% beneficial ownership and, absent shareholder approval, total issuances are capped at 11,386,834 shares, which the company states is 19.99% of the 56,952,652 shares outstanding as of June 30, 2026.
OneMedNet Corp Chief Executive Officer Aaron Green reported an open-market purchase of 36,650 shares of the company’s Common Stock. The shares were bought at an average price of $0.5733 per share in a single transaction.
Following this purchase, Green directly holds 1,896,375 shares of OneMedNet Common Stock, indicating that the transaction modestly increased his existing ownership position.
OneMedNet Corp Chief Medical Officer Jeffrey Yu reported a direct open-market purchase of 158,730 shares of Common Stock at $0.63 per share. This reflects a $100,000 investment under a subscription agreement dated June 23, 2026. After this transaction, he directly holds 8,780,410 shares. An additional 1,311,970 shares are held in a trust for his children with an independent trustee, where he has no investment control and disclaims beneficial ownership.
OneMedNet Corp Chief Medical Officer Jeffrey Yu made a substantial open-market purchase of company stock. On June 16, 2026, he bought 172,414 shares of common stock at $0.58 per share under a subscription agreement for a $100,000 investment.
Following this purchase, Yu directly holds 8,621,680 shares of OneMedNet common stock. The filing also reports 1,311,970 shares held indirectly in a trust for his children with an independent trustee, for which he has no investment control and disclaims beneficial ownership.
OneMedNet Corp director and CEO Aaron Green reported open-market purchases of the company’s Common Stock. On June 12, 2026, he bought 36,920 shares at an average price of $0.5581 per share. On June 15, 2026, he bought an additional 18,702 shares at an average price of $0.5396 per share.
After these transactions, Green directly owned 1,859,725 Common Stock shares. A footnote explains that one of the reported prices is a weighted average for multiple trades executed between $0.5463 and $0.5625 per share.
OneMedNet Corp director and 10% owner Thomas Kosasa bought 158,730 shares of common stock at $0.63 per share. The $100,000 investment was made on June 12, 2026 through a subscription agreement, with the share price based on the 10-day volume-weighted average price. Following this purchase, Kosasa directly holds 17,088,874 shares of OneMedNet.
OneMedNet Corp director and 10% owner Thomas Kosasa bought additional common stock. On May 18, 2026, he acquired 268,817 shares of OneMedNet common stock at a reported price of $0.93 per share, increasing his direct holdings to 16,930,144 shares.
The purchase was made through a $250,000 investment in OneMedNet under a subscription agreement, with the shares valued at the volume-weighted average price for the 10 trading days immediately before the purchase date.
OneMedNet Corporation is offering up to 11,500,000 shares of common stock in a primary offering. This prospectus supplement (No. 4) to the Prospectus (S-1, Registration No. 333-276130) also registers the resale of up to 28,152,560 shares by selling stockholders.
The supplement attaches the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and updates the Prospectus. Key near-term facts disclosed include shares outstanding of 54,433,407 as of May 12, 2026, a net loss of $2.45 million for the three months ended March 31, 2026, a cash balance of $233,000, and a Bitcoin holding with a reported fair value of $66,000 as of March 31, 2026. The filing also discloses a SEPA facility allowing up to $25.0 million of Common Stock sales subject to certain limitations and conditions.